Evidence map›Paper›PMID 39868766›Full record

Trial reportHuman vaccines & immunotherapeutics2025

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial.

Jelena Tica, Veronica V Rezelj, Benoit Baron, Vitalija van Paassen, Javier Zaidman, Lee Fairlie, Gert Scheper, Mathieu Le Gars, Frank Struyf, Macaya Douoguih and 3 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jelena TicaScientific Affairs and Late Development, Janssen-Cilag GmbH, Neuss, Germany.
Veronica V RezeljBiomarkers, Viral Vaccines, Janssen Vaccines and Prevention, Leiden, The Netherlands.
Benoit BaronBiostatistics - Vaccines, Janssen Vaccines and Prevention, Leiden, The Netherlands.
Vitalija van PaassenBiostatistics - Vaccines, Janssen Vaccines and Prevention, Leiden, The Netherlands.
Javier ZaidmanCIPREC, Centro Medico Arenales, Caba, Argentina.
Lee FairlieMaternal and Child Health, Wits RHI Shandukani, Johannesburg, South Africa.
Gert ScheperVaccine Research, Janssen Vaccines and Prevention, Leiden, The Netherlands.
Mathieu Le GarsBiomarkers, Viral Vaccines, Janssen Vaccines and Prevention, Leiden, The Netherlands.
Frank StruyfScientific Affairs and Late Development, Janssen Research and Development, Beerse, Belgium.
Macaya DouoguihClinical Development and Medical Affairs, Janssen Vaccines and Prevention, Leiden, The Netherlands.
Javier Ruiz-GuiñazúCrucell Integration, Janssen Research and Development, Beerse, Belgium.
COV3006 study group
COV3006 Study Group Collaborators

Funding

International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Units for HIV/AIDS Clinical Trials NetworksU01AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI SANNE, IAN MATTHIAS · 2007 to 2011
$24.2M
NIAID NIH HHS U01 AI068632NIAID NIH HHS U01 AI069463NIAID NIH HHS UM1 AI069463
6 · The paper itself

Abstract

We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 10

Indexed as

COVID-19COVID-19 VaccinesImmunogenicity, VaccineSARS-CoV-2Ad26COVS1AdolescentAntibodies, NeutralizingAntibodies, ViralChildFemaleHumansImmunization ScheduleImmunization, SecondaryMaleAd26COVS1Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesAd26.COV2.SadolescentCOVID-19 vaccinedose-range studyimmunogenicitysafetyshelf lifevirus vector vaccine

Identifiers

PMID39868766
PMCPMC11776467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.